Ubs Asset Management Americas Inc Neurocrine Biosciences Inc Transaction History
Ubs Asset Management Americas Inc
- $345 Billion
- Q2 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 912,064 shares of NBIX stock, worth $104 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
912,064
Previous 599,424
52.16%
Holding current value
$104 Million
Previous $82.7 Million
51.88%
% of portfolio
0.04%
Previous 0.03%
Shares
27 transactions
Others Institutions Holding NBIX
# of Institutions
641Shares Held
95.3MCall Options Held
661KPut Options Held
227K-
Black Rock Inc. New York, NY14.2MShares$1.62 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.15 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$526 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$282 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$270 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...